NYKODE THERAPEUTICS |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.24 NOK | +2.00% |
|
+0.61% | -38.13% |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 21,356 | 23,372 | 8,287 | 6,988 | 4,323 | - | - |
| Enterprise Value (EV) 1 | 21,356 | 21,490 | 6,164 | 5,327 | 3,069 | 3,314 | 4,323 |
| P/E ratio | 17.6 x | -307 x | -18.1 x | -16.8 x | -7.11 x | -6.38 x | -4.8 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | 74.5 x | 88.8 x | 49.5 x | 27.5 x | 22.8 x | 20.4 x |
| EV / Revenue | - | 68.5 x | 66.1 x | 37.8 x | 19.5 x | 17.5 x | 20.4 x |
| EV / EBITDA | - | -244 x | -11.4 x | -8.99 x | -4.6 x | -4.34 x | -3.72 x |
| EV / FCF | - | 8,641 x | -25.5 x | -5.11 x | -5.75 x | -3.96 x | -3.06 x |
| FCF Yield | - | 0.01% | -3.92% | -19.6% | -17.4% | -25.2% | -32.7% |
| Price to Book | - | - | 5.11 x | 3.85 x | 3.34 x | 4.04 x | - |
| Nbr of stocks (in thousands) | 284,785 | 289,619 | 294,694 | 326,546 | 326,546 | - | - |
| Reference price 2 | 74.99 | 80.70 | 28.12 | 21.40 | 13.24 | 13.24 | 13.24 |
| Announcement Date | 4/21/21 | 3/31/22 | 2/28/23 | 2/28/24 | - | - | - |
1NOK in Million2NOK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 12.45 | - | 313.5 | 93.31 | 141.1 | 157 | 189.9 | 212.3 |
| EBITDA 1 | -98.76 | - | -87.93 | -542.7 | -592.6 | -667.1 | -762.9 | -1,164 |
| EBIT 1 | -98.89 | - | -94.36 | -549.3 | -615.1 | -692.4 | -791.2 | -1,201 |
| Operating Margin | -794.57% | - | -30.1% | -588.66% | -435.95% | -440.91% | -416.68% | -565.5% |
| Earnings before Tax (EBT) 1 | -95.96 | - | -97.36 | -526.9 | -466.9 | -635.6 | -772.3 | -1,227 |
| Net income 1 | - | 1,249 | -82.32 | -441.7 | -372.3 | -613.2 | -735.1 | -1,227 |
| Net margin | - | - | -26.26% | -473.34% | -263.86% | -390.48% | -387.11% | -578% |
| EPS 2 | -0.3491 | 4.253 | -0.2627 | -1.550 | -1.271 | -1.862 | -2.076 | -2.760 |
| Free Cash Flow 1 | - | - | 2.487 | -241.5 | -1,043 | -533.7 | -836.3 | -1,412 |
| FCF margin | - | - | 0.79% | -258.79% | -739.52% | -339.84% | -440.42% | -665% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 4/15/20 | 4/21/21 | 3/31/22 | 2/28/23 | 2/28/24 | - | - | - |
1NOK in Million2NOK
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 278.3 | 33.2 | 13.02 | 34.1 | 33.3 | 54.2 | 30.31 | 24.14 | 66.89 | 66.89 | 66.89 | 66.89 |
| EBITDA 1 | 132.5 | -94.91 | -197.4 | - | - | -121.1 | -148.4 | -175.6 | -157.1 | -161.4 | -165.6 | -169.9 |
| EBIT 1 | 128.8 | -99.37 | -202.1 | -148.6 | - | -126.9 | -154.3 | -181.6 | -163.5 | -167.7 | -172 | -176.2 |
| Operating Margin | 46.28% | -299.33% | -1,552.65% | -435.82% | - | -234.1% | -509.11% | -752.19% | -244.45% | -250.8% | -257.14% | -263.49% |
| Earnings before Tax (EBT) 1 | 133.9 | -105.9 | -194.9 | -127.2 | - | -108.7 | -133.9 | -100.2 | -169.9 | -174.1 | -178.4 | -182.6 |
| Net income 1 | 94.31 | -84.85 | -151.2 | -126.1 | - | -97.9 | -110.5 | -56.53 | -169.9 | -174.1 | -178.4 | -182.6 |
| Net margin | 33.89% | -255.59% | -1,161.39% | -369.88% | - | -180.61% | -364.43% | -234.12% | -253.97% | -260.32% | -266.67% | -273.02% |
| EPS 2 | - | - | - | -0.4134 | - | -0.3188 | -0.3235 | -0.2118 | -0.5310 | -0.5310 | -0.5310 | -0.5310 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/31/22 | 8/23/22 | 11/23/22 | 2/28/23 | 5/12/23 | 8/22/23 | 11/15/23 | 2/28/24 | - | - | - | - |
1NOK in Million2NOK
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | - | - | 1,882 | 2,123 | 1,661 | 1,255 | 1,009 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | 2.49 | -241 | -1,043 | -534 | -836 | -1,412 |
| ROE (net income / shareholders' equity) | - | - | -5.05% | -24.3% | -21.4% | -32.9% | -66.1% | - |
| ROA (Net income/ Total Assets) | - | - | -3.8% | -17.6% | - | -25.8% | -30.3% | - |
| Assets 1 | - | - | 2,167 | 2,516 | - | 2,377 | 2,426 | - |
| Book Value Per Share 2 | - | - | - | 5.510 | 5.550 | 3.970 | 3.280 | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | - | - | - | 27.6 | 20.1 | 15.9 | 14.4 | 42.5 |
| Capex / Sales | - | - | - | 29.62% | 14.28% | 10.12% | 7.58% | 20% |
| Announcement Date | 4/15/20 | 4/21/21 | 3/31/22 | 2/28/23 | 2/28/24 | - | - | - |
1NOK in Million2NOK
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
13.24
NOK
Average target price
43
NOK
Spread / Average Target
+224.77%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -38.13% | 384M | |
| -2.63% | 103B | |
| +1.62% | 95.28B | |
| +1.46% | 22.15B | |
| -16.67% | 21.02B | |
| -8.58% | 18.15B | |
| -38.74% | 16.73B | |
| -13.21% | 16.05B | |
| +5.41% | 13.68B | |
| +33.57% | 12.17B |
- Stock Market
- Equities
- VACC Stock
- Financials Nykode Therapeutics
